Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
- PDF / 1,032,736 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 203 Views
REVIEW
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review Vincent Martin . Karen Hamrick Samaan . Sheena Aurora . Eric M. Pearlman . Chunmei Zhou . Xiaoping Li . Robert Pallay
Received: December 17, 2019 Ó The Author(s) 2020
ABSTRACT Migraine is a debilitating neurologic disease. People who experience migraine can have substantial disability, impaired functioning and a decreased quality of life (QoL). Expert recommendations suggest that people with frequent migraine attacks or severe impairment related to attacks may benefit from preventive treatment. Despite these recommendations and the existence of evidence-based guidelines for the use of preventive medication, many people who are candidates for preventive therapies do not receive them. Thus, there is still a substantial unmet need for preventive migraine treatment. Calcitonin gene-related peptide (CGRP) has a demonstrated role in the pathophysiology of migraine. Galcanezumab-gnlm (galcanezumab) Enhanced Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare. 12024333. V. Martin University of Cincinnati, Cincinnati, OH, USA K. H. Samaan (&) E. M. Pearlman Lilly USA, LLC, Indianapolis, IN, USA e-mail: [email protected] S. Aurora C. Zhou X. Li Eli Lilly and Company, Indianapolis, IN, USA R. Pallay Department of Family Medicine, Mercer University School of Medicine, Savannah, GA, USA
is a humanized monoclonal antibody that binds to the CGRP ligand and prevents binding to its receptor. It is administered as a once-monthly subcutaneous injection. The aim of this review is to present a comprehensive overview of the existing short- and long-term efficacy and safety data for galcanezumab in patients with migraine. Data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies show that galcanezumab treatment for 3 or 6 months results in overall reduction in mean monthly migraine headache days in patients with episodic (EVOLVE-1 and EVOLVE-2) and chronic (REGAIN) migraine. Greater proportions of patients with episodic migraine receiving galcanezumab versus placebo demonstrated a C 50%, C 75% and 100% response to therapy and reported a lower level of disability and an improvement in functioning and QoL. Similarly, when compared with placebo, greater proportions of patients with chronic migraine treated with galcanezumab demonstrated a C 50% and C 75% response and reported improved functioning. A 12-month open-label study demonstrated the continued efficacy of galcanezumab for up to 12 months. In all studies galcanezumab was well tolerated. In conclusion, data from pivotal studies show that galcanezumab may fulfill an unmet need in the treatment of patients with migraine who require preventive therapy.
Adv Ther
PLAIN LANGUAGE SUMMARY Migraine is a significant contributor to the global burden of disease. Migraine symptoms can lead to substantial disability and can significantly impact an individual’s ability to perform ever
Data Loading...
